Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Current Deferred Revenue (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Current Deferred Revenue for 14 consecutive years, with $381000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 3.05% year-over-year to $381000.0, compared with a TTM value of $381000.0 through Dec 2025, down 3.05%, and an annual FY2025 reading of $381000.0, down 3.05% over the prior year.
  • Current Deferred Revenue was $381000.0 for Q4 2025 at Fate Therapeutics, up from $5000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $42.2 million in Q4 2022 and bottomed at $5000.0 in Q3 2025.
  • Average Current Deferred Revenue over 5 years is $12.8 million, with a median of $1.8 million recorded in 2023.
  • The sharpest move saw Current Deferred Revenue surged 619.57% in 2021, then tumbled 99.17% in 2025.
  • Year by year, Current Deferred Revenue stood at $21.5 million in 2021, then skyrocketed by 96.56% to $42.2 million in 2022, then plummeted by 98.38% to $685000.0 in 2023, then crashed by 42.63% to $393000.0 in 2024, then fell by 3.05% to $381000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for FATE at $381000.0 in Q4 2025, $5000.0 in Q3 2025, and $212000.0 in Q1 2025.